RRSO is typically recommended for patients aged between 35 and 40 years and upon completion of childbearing for breast cancer patients with BRCA1 pathological variants, and between 40 and 45 years for BRCA2 pathological variants [5]. Here, BRCA1 is linked to breast carcinoma.